GlassScriptPhysician profile
John W Finnie
NPI 1023088564
$14,020.24
in general payments reported to CMS, 2019-2025
69 companies · $2,360 in 2025
The $2,360 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,834 · 2020: $519 · 2021: $362 · 2022: $2,707 · 2023: $2,900 · 2024: $2,340 · 2025: $2,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,394 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,393.71 |
| Education | $204.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,280.58 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $1,053.15 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| E.R. Squibb & Sons, L.L.C. | $894.89 | 2019-2025 | Opdivo, Opdualag |
| Emd Serono, INC. | $873.37 | 2019-2025 | Bavencio |
| Daiichi Sankyo INC. | $790.25 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $719.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $641.80 | 2019-2025 | |
| Genzyme Corporation | $563.40 | 2019-2025 | |
| Genentech USA, INC. | $509.71 | 2019-2025 | Tecentriq, Herceptin, Perjeta |
| Seagen INC. | $494.13 | 2019-2023 | Tukysa, Padcev |
| Janssen Biotech, INC. | $485.29 | 2019-2025 | Erleada, Rybrevant, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $430.75 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Incyte Corporation | $429.54 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $395.76 | 2019-2025 | Trodelvy |
| Abbvie INC. | $340.39 | 2019-2025 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $293.93 | 2019-2023 | Kyprolis, Lumakras |
| Eisai INC. | $282.95 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $191.11 | 2023-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $188.90 | 2019-2025 | Iclusig, Fruzaqla, Alunbrig |
| Beigene USA, INC. | $183.67 | 2022-2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $165.98 | 2019-2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $161.60 | 2019-2024 | |
| Array Biopharma INC | $158.04 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Kite Pharma, INC. | $157.19 | 2020-2025 | Yescarta |
| Astellas Pharma US INC | $145.61 | 2019-2025 | Vyloy, Padcev, Xtandi |
| Lilly USA, LLC | $142.50 | 2019-2023 | Jaypirca, Verzenio |
| Rigel Pharmaceuticals, INC. | $136.09 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Glaxosmithkline, LLC. | $130.68 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Karyopharm Therapeutics INC. | $125.93 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.63 | 2019-2025 | Gilotrif |
| Sanofi-Aventis U.S. LLC | $99.95 | 2021 | |
| Exelixis INC. | $92.37 | 2019-2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $92.03 | 2019-2024 | |
| Gt Medical Technologies, INC | $85.32 | 2022-2024 | Gammatile, Gammatile |
| Servier Pharmaceuticals LLC | $74.68 | 2022-2025 | |
| Geron Corporation | $67.20 | 2025 | Rytelo |
| Sun Pharmaceutical Industries INC. | $56.04 | 2019-2023 | Yonsa, Odomzo |
| Mirati Therapeutics, INC. | $54.96 | 2023 | Krazati |
| Blueprint Medicines Corporation | $53.58 | 2022-2024 | Ayvakit |
| Tersera Therapeutics LLC | $52.47 | 2022-2023 | Zoladex |
| Kyowa Kirin, INC. | $51.48 | 2021-2023 | Poteligeo |
| Adc Therapeutics America, INC. | $50.73 | 2023-2024 | |
| Secura Bio, INC. | $49.39 | 2019-2022 | |
| Taiho Oncology, INC. | $48.55 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $45.36 | 2023-2024 | Orgovyx |
| Stemline Therapeutics INC. | $41.86 | 2023-2024 | Elzonris, Orserdu |
| G1 Therapeutics, INC. | $41.64 | 2023 | Cosela |
| Epizyme, INC. | $38.23 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $34.28 | 2025 | Provenge |
| Legend Biotech USA INC. | $29.86 | 2025 | Carvykti |
| Adaptive Biotechnologies Corporation | $29.48 | 2022 | |
| Coherus Oncology, INC. | $28.70 | 2022 | |
| Clovis Oncology, INC. | $28.55 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $26.96 | 2025 | Enjaymo |
| Foundation Medicine, INC. | $24.39 | 2023 | |
| Springworks Therapeutics, INC. | $21.04 | 2024 | Ogsiveo |
| Myovant Sciences INC. | $20.51 | 2021 | |
| Corcept Therapeutics | $20.23 | 2025 | Korlym |
| Agios Pharmaceuticals, INC. | $18.90 | 2019 | |
| Beone Medicines USA, INC. | $17.63 | 2025 | Tevimbra |
| Sobi, INC | $16.72 | 2022 | |
| Morphosys, US INC. | $16.28 | 2022 | |
| Global Blood Therapeutics, INC. | $15.92 | 2021 | |
| Genmab U.S., INC. | $15.22 | 2022 | |
| Cti Biopharma Corp. | $14.95 | 2023 | Vonjo |
| Aveo Pharmaceuticals, INC. | $14.31 | 2023 | Fotivda |
| Tempus Ai, INC | $13.48 | 2024 | |
| Verastem, INC. | $13.27 | 2019 | |
| Dova Pharmaceuticals | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Finnie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.